image
Healthcare - Biotechnology - NASDAQ - US
$ 31.64
-3.06 %
$ 3 B
Market Cap
-12.07
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one SRRK stock under the worst case scenario is HIDDEN Compared to the current market price of 31.6 USD, Scholar Rock Holding Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one SRRK stock under the base case scenario is HIDDEN Compared to the current market price of 31.6 USD, Scholar Rock Holding Corporation is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one SRRK stock under the best case scenario is HIDDEN Compared to the current market price of 31.6 USD, Scholar Rock Holding Corporation is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart SRRK

image
$50.0$50.0$45.0$45.0$40.0$40.0$35.0$35.0$30.0$30.0$25.0$25.0$20.0$20.0Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
0 REVENUE
0.00%
-252 M OPERATING INCOME
-47.15%
-246 M NET INCOME
-48.56%
-201 M OPERATING CASH FLOW
-38.37%
-76.1 M INVESTING CASH FLOW
-184.87%
353 M FINANCING CASH FLOW
244.17%
0 REVENUE
0.00%
-69.4 M OPERATING INCOME
-7.07%
-66.5 M NET INCOME
-3.06%
-49.5 M OPERATING CASH FLOW
5.61%
-195 M INVESTING CASH FLOW
-553.33%
346 M FINANCING CASH FLOW
208556.63%
Balance Sheet Scholar Rock Holding Corporation
image
Current Assets 451 M
Cash & Short-Term Investments 437 M
Receivables 2.15 M
Other Current Assets 11.7 M
Non-Current Assets 23.8 M
Long-Term Investments 0
PP&E 18.4 M
Other Non-Current Assets 5.35 M
92.07 %3.88 %Total Assets$474.9m
Current Liabilities 46.9 M
Accounts Payable 10.1 M
Short-Term Debt 5.77 M
Other Current Liabilities 31.1 M
Non-Current Liabilities 59.4 M
Long-Term Debt 59.4 M
Other Non-Current Liabilities 0
9.50 %5.43 %29.23 %55.84 %Total Liabilities$106.3m
EFFICIENCY
Earnings Waterfall Scholar Rock Holding Corporation
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 252 M
Operating Income -252 M
Other Expenses -5.76 M
Net Income -246 M
00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)000(252m)(252m)6m(246m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-66.81% ROE
-66.81%
-51.86% ROA
-51.86%
-58.11% ROIC
-58.11%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Scholar Rock Holding Corporation
image
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -246 M
Depreciation & Amortization 1.94 M
Capital Expenditures -98 K
Stock-Based Compensation 36.6 M
Change in Working Capital 6.59 M
Others 150 K
Free Cash Flow -201 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Scholar Rock Holding Corporation
image
Wall Street analysts predict an average 1-year price target for SRRK of $34.5 , with forecasts ranging from a low of $28 to a high of $42 .
SRRK Lowest Price Target Wall Street Target
28 USD -11.50%
SRRK Average Price Target Wall Street Target
34.5 USD 9.04%
SRRK Highest Price Target Wall Street Target
42 USD 32.74%
Price
Max Price Target
Min Price Target
Average Price Target
50504545404035353030252520201515101055Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 19
6. Ownership
Insider Ownership Scholar Rock Holding Corporation
image
Sold
0-3 MONTHS
9.85 M USD 8
3-6 MONTHS
85.7 M USD 8
6-9 MONTHS
44.9 M USD 6
9-12 MONTHS
187 K USD 4
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the company granted inducement equity awards covering an aggregate of 156,650 shares of its common stock to 19 newly hired employees, consisting of inducement stock options to purchase an aggregate of 89,515 shares of common stock and. businesswire.com - 2 weeks ago
FDA Grants Priority Review for Biologics License Application (BLA) and EMA Accepts Marketing Authorisation Application (MAA) for Apitegromab as a Treatment for Spinal Muscular Atrophy CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for apitegromab, an investigational muscle-targeted treatment that is being developed to provide clinically meaningful improvement in motor function for. businesswire.com - 1 month ago
Scholar Rock Stock Jumps On Additional Data From Pivotal Trial Of Muscular Dystrophy Treatment Scholar Rock Holding Corp. SRRK said on Sunday the company will present new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. benzinga.com - 1 month ago
Scholar Rock Presents New Phase 3 SAPPHIRE Data at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for neuromuscular diseases, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that new efficacy and safety data from the Phase 3 pivotal SAPPHIRE trial (NCT05156320) will be presented in multiple clinical presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical &a. businesswire.com - 1 month ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 113,800 shares of its common stock to seven newly hired employees, consisting of inducement stock options to p. businesswire.com - 1 month ago
Scholar Rock Holding Corporation (SRRK) Q4 2024 Earnings Call Transcript Scholar Rock Holding Corporation. (NASDAQ:SRRK ) Q4 2024 Earnings Conference Call February 27, 2025 8:15 AM ET Company Participants Jay Backstrom - President & CEO Ted Myles - COO & CFO Tracey Sacco - Chief Commercial Officer Conference Call Participants Allison Bratzel - Piper Sandler Michael Yee - Jefferies Tessa Romero - JPMorgan Gary Nachman - Raymond James Operator Good morning and welcome to Scholar Rock's Fourth Quarter Financial Results and Business Update Call. seekingalpha.com - 2 months ago
Scholar Rock to Present Additional Clinical Data from the Phase 3 SAPPHIRE Trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, announced today that it will present additional data from its Phase 3 SAPPHIRE clinical trial (NCT05156320) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March. businesswire.com - 2 months ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 371,500 shares of its common stock to eleven newly hired employees, consisting of inducement stock options to. businesswire.com - 2 months ago
Scholar Rock: More Than Just An SMA Biotech With Q2 2025 Obesity Treatment Data Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for Priority Review to be given. Apitegromab is being explored in the phase 2 proof-of-concept EMBRAZE study, given alongside GLP-1 drugs to treat patients with obesity; Data from this trial is expected in Q2 of 2025. Positive data from the phase 2 EMBRAZE study would lead to IND of SRK-439 in Q3 of 2025 to target obesity and other cardiometabolic disorders. seekingalpha.com - 3 months ago
Scholar Rock Submits Biologics License Application (BLA) to the U.S. FDA for Apitegromab as a Treatment for Patients with Spinal Muscular Atrophy (SMA) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration (FDA) for apitegromab, a muscle-targeted therapy designed and developed to provide clinically meaningfu. businesswire.com - 3 months ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy, cardiometabolic disorders, and other serious diseases where protein growth factors play a fundamental role, today announced that the company granted inducement equity awards covering an aggregate of 48,000 shares of its common stock to three newly hired employees, consisting of inducement stock options to pu. businesswire.com - 3 months ago
Scholar Rock Sets Sights on $2 Billion Apitegromab Revenue Amid Spinal Muscular Atrophy Market Growth Scholar Rock Holding Corporation SRRK President & CEO Jay Backstrom presented at the J.P. Morgan Healthcare Conference. benzinga.com - 3 months ago
8. Profile Summary

Scholar Rock Holding Corporation SRRK

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 3 B
Dividend Yield 0.00%
Description Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Contact 301 Binney Street, Cambridge, MA, 02142 https://scholarrock.com
IPO Date May 25, 2018
Employees 128
Officers Dr. Jing L. Marantz M.B.A., M.D., Ph.D. Chief Medical Officer Ms. Junlin Ho J.D. General Counsel & Corporate Secretary Ms. Lisa Amaya Price Senior Vice President of Human Resources Dr. Jay Thomas Backstrom M.D., M.P.H. President, Chief Executive Officer & Director Ms. Erin Moore CPA Interim Principal Financial & Accounting Officer Ms. Caryn Parlavecchio Chief Human Resources Officer Mr. Mo Qatanani Ph.D. Chief Scientific Officer Mr. Edward H. Myles MBA Senior Advisor Ms. Rushmie Nofsinger Vice President of Corporate Affairs & Investor Relations Mr. Ryan Iarrobino Senior Vice President of Clinical Development & Operations